These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
516 related articles for article (PubMed ID: 28423171)
1. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171 [TBL] [Abstract][Full Text] [Related]
2. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. Caudle AS; Yang WT; Mittendorf EA; Black DM; Hwang R; Hobbs B; Hunt KK; Krishnamurthy S; Kuerer HM JAMA Surg; 2015 Feb; 150(2):137-43. PubMed ID: 25517573 [TBL] [Abstract][Full Text] [Related]
3. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039 [TBL] [Abstract][Full Text] [Related]
4. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer. Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216 [TBL] [Abstract][Full Text] [Related]
5. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Newman EA; Sabel MS; Nees AV; Schott A; Diehl KM; Cimmino VM; Chang AE; Kleer C; Hayes DF; Newman LA Ann Surg Oncol; 2007 Oct; 14(10):2946-52. PubMed ID: 17514407 [TBL] [Abstract][Full Text] [Related]
6. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy. Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493 [TBL] [Abstract][Full Text] [Related]
7. Axillary staging using ultrasound-guided fine needle aspiration biopsy in locally advanced breast cancer. Oruwari JU; Chung MA; Koelliker S; Steinhoff MM; Cady B Am J Surg; 2002 Oct; 184(4):307-9. PubMed ID: 12383889 [TBL] [Abstract][Full Text] [Related]
8. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784 [TBL] [Abstract][Full Text] [Related]
9. Predictive value of axillary nodal imaging by magnetic resonance imaging based on breast cancer subtype after neoadjuvant chemotherapy. Steiman J; Soran A; McAuliffe P; Diego E; Bonaventura M; Johnson R; Ahrendt G; McGuire K J Surg Res; 2016 Jul; 204(1):237-41. PubMed ID: 27451892 [TBL] [Abstract][Full Text] [Related]
10. Predicting breast and axillary response after neoadjuvant treatment for breast cancer: The role of histology vs receptor status. Vugts G; Van den Heuvel F; Maaskant-Braat AJG; Voogd AC; Van Warmerdam LJC; Nieuwenhuijzen GAP; Van der Sangen MJC Breast J; 2018 Nov; 24(6):894-901. PubMed ID: 30033607 [TBL] [Abstract][Full Text] [Related]
11. A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer. Kantor O; Sipsy LM; Yao K; James TA Ann Surg Oncol; 2018 May; 25(5):1304-1311. PubMed ID: 29368152 [TBL] [Abstract][Full Text] [Related]
12. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Kuerer HM; Rauch GM; Krishnamurthy S; Adrada BE; Caudle AS; DeSnyder SM; Black DM; Santiago L; Hobbs BP; Lucci A; Gilcrease M; Hwang RF; Candelaria RP; Chavez-MacGregor M; Smith BD; Arribas E; Moseley T; Teshome M; Miggins MV; Valero V; Hunt KK; Yang WT Ann Surg; 2018 May; 267(5):946-951. PubMed ID: 28549010 [TBL] [Abstract][Full Text] [Related]
13. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528 [TBL] [Abstract][Full Text] [Related]
14. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy. Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375 [TBL] [Abstract][Full Text] [Related]
15. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596 [TBL] [Abstract][Full Text] [Related]
16. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Boughey JC; McCall LM; Ballman KV; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton T; Hunt KK Ann Surg; 2014 Oct; 260(4):608-14; discussion 614-6. PubMed ID: 25203877 [TBL] [Abstract][Full Text] [Related]
17. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Gimbergues P; Abrial C; Durando X; Le Bouedec G; Cachin F; Penault-Llorca F; Mouret-Reynier MA; Kwiatkowski F; Maublant J; Tchirkov A; Dauplat J Ann Surg Oncol; 2008 May; 15(5):1316-21. PubMed ID: 18311507 [TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla. Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563 [TBL] [Abstract][Full Text] [Related]
19. Can additional histopathological examination of ultrasound-guided axillary lymph node core biopsies improve preoperative diagnosis of primary breast cancer nodal metastasis? Mullen R; Purdie CA; Jordan LB; McLean D; Whelehan P; Vinnicombe S; Brown DC; Evans A Clin Radiol; 2013 Jul; 68(7):704-7. PubMed ID: 23518495 [TBL] [Abstract][Full Text] [Related]
20. Axillary nodal burden in primary breast cancer patients with positive pre-operative ultrasound guided fine needle aspiration cytology: management in the era of ACOSOG Z011. Boland MR; Prichard RS; Daskalova I; Lowery AJ; Evoy D; Geraghty J; Rothwell J; Quinn CM; O'Doherty A; McDermott EW Eur J Surg Oncol; 2015 Apr; 41(4):559-65. PubMed ID: 25648466 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]